Rc, Mishra
Mayo Clinic
Honorary Consultant Intensivist & Internist, Ahmedabad, India
Citations 1
Consensus Statement for Pharmacological Management of Coronavirus Disease 2019 (COVID-19): A Pragmatic Approach
Javeri, Yash , Ak, Khanna, AA, Tayar, BG, Jagiasi, JLP, Portilla, Zirpe, Kapil , Ka, Popugaev, MLNG, Malbrain, Ma, Kirkman, MTV, Chan, Mer, M, Harriss, Mohammed, Rangappa, Pradeep, Piacevoli, Q, Mani, RK, Rc, Mishra, Bagdia, S, Donovan, Suzanne, ST, Reza, TY, Yeh, Videtta, Walter , R, Jain, Nasa, Prashant , Kashyap, Rahul , Bhaskar, Balu , Jagiasi, Bharat G , Juneja, Deven , Lipman, Jeffrey , J, Ng, Hashmi, Madiha , Türkoğlu, Melda , M, Singer, Garg, Rakesh Kumar , Yadav, Rakesh Kumar , TY, Yeh
Asploro Journal of Biomedical and Clinical Case Reports | December 28, 2020 | Volume: 3 | Issue: 3 | Pages: 241-256
Introduction: In the absence of high-quality evidence for Coronavirus disease-2019 (COVID-19), supportive care is advocated during this pandemic. We aim to develop a consensus statement from global experts for pharmacological management, based on the pathophysiology of COVID-19. Material and Methods: We used a modified Delphi methodology in three steps: 1) Formulation of the steering committee and questionnaire; 2) Delphi methodology and selection of experts; 3) Final meeting of the steering committee and analysis, discussion, preparation, and presentation of captured data. Results: 34 (73·9%) experts accepted the invitation for the study. We conducted two rounds of Delphi and consensus (>70% votes) was achieved on 11 out of 24 statements after the end of round two. Conclusion: This global consensus suggests that “Anti-viral therapy should be administered in the early infection phase of COVID-19 followed by low dose steroid therapy in pulmonary phase. Prophylactic dose anticoagulation should be used in hospitalized, mild to moderate COVID-19 patients. We make no suggestions for the use of immune modulation therapy”.